Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 104, Issue 13, 2007, Pages 5584-5589

  Abraham, Sunny ^a   Guo, Fang ^a   Li, An Sheng ^a   Rader, Christoph ^a,b   Liu, Cheng ^a   Barbas III, Carlos F ^a   Lerner, Richard A ^a   Sinha, Subhash C ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Ab conjugate; Aldolase Ab; Doxorubicin; Integrin v 3

Indexed keywords

ANTIBODY CONJUGATE; DOXORUBICIN; PRODRUG; VITRONECTIN RECEPTOR; ANTIBODY; CATALYTIC ANTIBODY; CYSTEINE; SULFIDE;

ANTIBODY PRODUCTION; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG SYNTHESIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; BREAST TUMOR; CHEMICAL MODEL; CHEMISTRY; DRUG DESIGN; IMMUNOLOGY; METABOLISM; METHODOLOGY; PROTEIN BINDING; SYNTHESIS; TUMOR CELL LINE;

ANTIBODIES; ANTIBODIES, CATALYTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; CYSTEINE; DOXORUBICIN; DRUG DESIGN; FLOW CYTOMETRY; HUMANS; INTEGRIN ALPHAVBETA3; MODELS, CHEMICAL; PRODRUGS; PROTEIN BINDING; SULFIDES;

EID: 34248363620     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.0700223104     Document Type: Article

References (25)

1. Tanaka F, Barbas CF, III (2005) in Catalytic Antibodies, ed Keinan E (Wiley-VCH, Weinheim, Germany), p 304.
2. Zhong G, Shabat D, List B, Anderson J, Sinha SC, Lerner RA, Barbas CF III (1998) Angew Chem Int Ed 37:2481-2484.
3. Sinha SC, Sun J, Miller G, Barbas CF, III, Lerner RA (1999) Org Lett 1:1623-1626.
4. Wagner J, Lerner RA, Barbas CF, III (1995) Science 270:1797-1800.
5. Zhong G, Lerner RA, Barbas CF, III (1999) Angew Chem Int Ed 38:3738-3741.
6. Shabat D, Rader C, List B, Lerner RA, Barbas CF, III (1999) Proc Natl Acad Sci USA 96:6925-6930.
7. Haba K, Popkov M, Shamis M, Lerner RA, Barbas CF, III, Shabat D (2005) Angew Chem Int Ed 44:716-720.
8. Sinha SC, Li L-S, Miller GP, Dutta S, Rader C, Lerner RA (2004) Proc Natl Acad Sci USA 101:3095-3099.
9. Sinha SC, Li L-S, Watanabe S-I, Kaltgrad E, Tanaka F, Rader C, Lerner RA, Barbas CF, III (2004) Chem Eur J 10:5467-5472.
10. Shamis M, Lode HN, Shabat D (2004) J Am Chem Soc 126:1726-1730.
11. Shabat D, Lode HN, Pertl U, Reisfeld RA, Rader C, Lerner RA, Barbas CF, III (2001) Proc Natl Acad Sci USA 98:7528-7533.
12. Bagshawe KD, Sharma SK, Begent RHJ (2004) Exp Opin Biol Ther 4:1777-1789.
13. Blackburn GM, Rickard JH, Cesaro-Tadic S, Lagos D, Mekhalfia A, Partridge L, Plueckthun A (2004) Pure Appl Chem 76:983-989.
14. Meyer A, Auernheimer J, Modlinger A, Kessler H (2006) Curr Pharmacol Des 12:2723-2747.
15. Rader C, Sinha SC, Popkov M, Lerner RA, Barbas CF, III (2003) Proc Natl Acad Sci USA 100:5396-5400.
16. Li L-S, Rader C, Matsushita M, Das S, Barbas CF, III, Lerner RA, Sinha SC (2004) J Med Chem 47:5630-5640.
17. Guo F, Das S, Mueller BM, Barbas CF, III, Lerner RA, Sinha SC (2006) Proc Natl Acad Sci USA 103:11009-11014.
18. Popkov M, Rader C, Gonzalez B, Sinha SC, Barbas CF, III (2006) Int J Cancer 119:1194-1207.
19. Satchi-Fainaro R, Wrasidlo W, Lode HN, Shabat D (2002) Bioorg Med Chem 10:3023-3029.
20. List B, Barbas CF, III, Lerner RA (1998) Proc Natl Acad Sci USA 95:15351-15355.
21. Rader C, Turner JM, Heine A, Shabat D, Sinha SC, Wilson IA, Lerner RA, Barbas CF, III (2003) J Mol Biol 332:889-899.
22. Azoulay M, Florent J-C, Monneret C, Gesson JP, Jacquesy J-C, Tillequin F, Koch M, Bosslet K, Czech J, Hoffman D (1995) Anti-Cancer Drug Des 10:441-450.
23. Hoffmann T, Zhong G, List B, Shabat D, Anderson J, Gramatikova S, Lerner RA, Barbas CF, III (1998) J Am Chem Soc 120:2768-2779.
24. Mukaiyama T, Banno K, Narasaka K (1974) J Am Chem Soc 96:7503-7509.
25. Baker-Glenn C, Hodnett N, Reiter M, Ropp S, Ancliff R, Gouverneur V (2005) J Am Chem Soc 127:1481-1486.